1177.HK
Sino Biopharmaceutical Limited
Healthcare · ·
$4.53
Data: 2026-05-28
✓ ETHICAL PASS
STRONG MOAT
MODERATE
Data Confidence: 71.4%
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$11.0B
Total market value of the company
Rev Growth
+9.8%
Year-over-year revenue change
Profit Margin
N/A
How much profit the company keeps from each dollar of revenue
Analyst Target
N/A
Recommendation
N/A
Consensus view from ? analysts covering this stock
About Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others.
Country: Hong Kong Industry: Biotechnology
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
N/A
Core business does not involve prohibited activities
Debt Ratio
0.0%
Debt must be below 33% of total assets
Cash Ratio
0.0%
Interest-bearing cash below 33% of assets
Receivables
0.0%
Receivables below 49% of assets
Revenue Purity
0.0%
Non-compliant revenue below 5% — any excess requires purification
Valuation
Rating
Overall assessment combining ethics, valuation, and quality
Ethical Score
N/A
Valuation Score
61.0
Quality Score
43.8
Combined
41.4
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Annual Return
34.4%
Historical annualised return based on price data
Days in State
162
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
N/A
52W High
$N/A
52W Low
$N/A
Avg Volume
N/A
Average daily shares traded — higher means easier to buy and sell
Short % Float
N/A
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
N/A
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
20.2%
Profit from core operations before interest and tax
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
N/A
Loss-making — spending exceeds revenue after all costs
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28